advertisement
Abstract #19143 Published in IGR 3-1
Dorzolamide-induced immune thrombocytopenia: a case report and literature review
Martin XD; Danese MJournal of Glaucoma 2001; 10: 133-135
PURPOSE: To report a severe case of dorzolamide-induced immune thrombocytopenia, to review the literature on this topic, and to draw attention to the serious potential side effects of this topical sulfonamide. CASE REPORTS: An 83-year-old man with primary open-angle glaucoma in both eyes who had been taking topical dorzolamide therapy for 3.5 years developed a severe thrombocytopenia (10,000 platelets/μl). The amount of platelets was not influenced by prednisone therapy but increased rapidly to 100,000/μl after the withdrawal of dorzolamide. LITERATURE REVIEW: Although the potential capacity of sulfonamides to induce thrombocytopenia is well known, no case of dorzolamide-induced immune thrombocytopenia was published in the medical literature until July 2000. CONCLUSIONS: Considering the possible severe side effects that can be induced by topical dorzolamide 2%, ophthalmologists should carefully evaluate during the medical history of their patients the risk of sensitivity to sulfonamides.
Dr. X.D. Martin, 64 Avenue de Rumine, CH-1005, Lausanne, Switzerland
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
